selepressin
Small moleculeexperimental
Selepressin is a potent, highly selective, short-acting peptide full agonist of the vasopressin 1A receptor and analog of vasopressin which was under development by Ferring Pharmaceuticals for the treatment of vasodilatory hypotension in septic shock. — Wikipedia
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2009 (NCT01000649)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Vasopressin V1a receptorAGONIST
AVPR1A agonist
Peptide
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCC(N)=O)NC1=O- Mol. weight
- 1048.3 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSelepressin ↗
- ChEMBLCHEMBL1817709 ↗
Also known as
- 2-phe-3-ile-4-hgn-8-orn(ipr)-vasopressin
- fe202158
- fe 202158
- fe 202158
- fe 202158
- fe-202158
- fe-202158
- fe-202158
- (phe2,ile3,hgn4,orn(ipr)8)vasopressin
- selepressin
- selepressin
- selepressin
- selepressin
- vasopressin, phe(2)-ile(3)-hgn(4)-orn(ipr)(8)-
- vasopressin, phenylalanyl(2)-isoleucyl(3)-hgn(4)-ornithyl(isopropyl)(8)-
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02508649 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2015 | Ferring |
| NCT01612676 | Phase 2 | Jun 1, 2012 | Ferring |
| NCT01000649 | Phase 2 | Nov 1, 2009 | Ferring |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ferring | For profit | 3 | 3 | 2 | 2009 |
1 organizations
Page 1 / 1